Amylyx Pharmaceuticals AMLX
$26.02 −$0.18 (-0.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $25.55 -1.81%
Open$25.64
Prev close$26.20
Day range$25.52 – $26.40
Volume1.14M
Market cap$3.35B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$49.66M-37.8% YoY
Net profit-$45.49M-32.3% YoY
Diluted EPS-$0.38-2.7% YoY
Free cash flow-$33.70M-10.9% YoY
Operating cash flow-$33.67M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-30.1%
Return on assets-28.4%
Return on invested capital-32.0%
Current ratio26.81
Liabilities / assets4.2%
Cash & investments$768.13M
Total debt$4.01M
Net cash (debt)$764.12M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $49.66M | $45.69M | $43.78M | $153.29M | $36.61M |
| Selling and Admin Expenses | $21.31M | $21.93M | $16.17M | $62.89M | $15.39M |
| Research & Development | $28.35M | $23.77M | $27.61M | $90.40M | $21.21M |
| Operating Profit | -$49.66M | -$45.69M | -$43.78M | -$153.29M | -$36.61M |
| Net Non-Operating Interest Income (Expense) | $4.18M | $2.32M | $2.57M | $9.30M | $3.29M |
| Non-Operating Interest Income | $4.18M | $2.32M | $2.57M | $9.30M | $3.29M |
| Other Income (Expense) | -$14,000.00 | -$53,000.00 | -$75,000.00 | -$700,000.00 | $362,000.00 |
| Other Non-Operating Income (Expenses) | -$14,000.00 | -$53,000.00 | -$75,000.00 | -$700,000.00 | $362,000.00 |
| Pretax Profit | -$45.49M | -$43.42M | -$41.28M | -$144.69M | -$32.95M |
| Net Profit | -$45.49M | -$43.42M | -$41.28M | -$144.74M | -$33.00M |
| Profit from Continuing Operations | -$45.49M | -$43.42M | -$41.28M | -$144.74M | -$33.00M |
| Net Income to Parent Company | -$45.49M | -$43.42M | -$41.28M | -$144.74M | -$33.00M |
| Net Income to Common Stockholders | -$45.49M | -$43.42M | -$41.28M | -$144.74M | -$33.00M |
| Basic EPS | -$0.38 | -$0.39 | -$0.37 | -$1.53 | -$0.30 |
| Diluted EPS | -$0.38 | -$0.39 | -$0.37 | -$1.53 | -$0.30 |
| Total Revenue as Reported | – | – | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | – | – | $0.00 | $0.00 | $0.00 |
| Gross Profit | – | – | $0.00 | $0.00 | $0.00 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $0.00 | $0.00 |
| Tax | – | – | – | $46,000.00 | $46,000.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $786.80M | $264.56M | $293.60M | $332.65M | $332.65M |
| Total Current Assets | $778.86M | $256.34M | $285.02M | $323.67M | $323.67M |
| Cash and Cash Equivalents & Short-Term Investments | $768.13M | $250.76M | $279.77M | $316.98M | $316.98M |
| -Cash and Cash Equivalents | $240.10M | $49.33M | $229.14M | $226.65M | $226.65M |
| -Short Term Investments | $528.04M | $201.43M | $50.63M | $90.33M | $90.33M |
| Other Current Assets | $10.73M | $5.58M | $5.26M | $6.60M | $6.60M |
| Total Non-Current Assets | $7.94M | $8.23M | $8.58M | $8.97M | $8.97M |
| Net PPE | $4.44M | $4.74M | $5.09M | $5.49M | $5.49M |
| -Gross PPE | $4.44M | $4.74M | $5.09M | $7.05M | $7.05M |
| Other Non-Current Assets | $3.50M | $3.49M | $3.49M | $3.48M | $3.48M |
| Total Liabilities | $33.06M | $25.40M | $20.44M | $27.39M | $27.39M |
| Total Current Liabilities | $29.05M | $21.15M | $15.97M | $22.69M | $22.69M |
| Payables | $4.80M | $5.53M | $3.53M | $3.52M | $3.52M |
| -Accounts Payable | $4.80M | $5.53M | $3.53M | $3.52M | $3.52M |
| Current Accrued Expenses | $13.86M | $8.98M | $8.09M | $7.86M | $7.86M |
| Short-Term Debt and Capital Lease Obligation | $932,000.00 | $1.01M | $1.16M | $1.26M | $1.26M |
| -Current Capital Lease Obligation | $932,000.00 | $1.01M | $1.16M | $1.26M | $1.26M |
| Total Non-Current Liabilities | $4.01M | $4.25M | $4.48M | $4.70M | $4.70M |
| Long Term Debt and Capital Lease Obligation | $4.01M | $4.25M | $4.48M | $4.70M | $4.70M |
| -Long Term Capital Lease Obligation | $4.01M | $4.25M | $4.48M | $4.70M | $4.70M |
| Total Equity | $753.74M | $239.17M | $273.16M | $305.26M | $305.26M |
| Stockholders' Equity | $753.74M | $239.17M | $273.16M | $305.26M | $305.26M |
| Capital Stock | $13,000.00 | $11,000.00 | $11,000.00 | $11,000.00 | $11,000.00 |
| -Common Stock | $13,000.00 | $11,000.00 | $11,000.00 | $11,000.00 | $11,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | – | – |
| Additional Paid-In Capital | $1.64B | $1.08B | $1.07B | $1.06B | $1.06B |
| Retained Earnings | -$881.62M | -$836.13M | -$792.71M | -$751.43M | -$751.43M |
| Gains/Losses Not Affecting Retained Earnings | -$179,000.00 | $19,000.00 | $240,000.00 | $404,000.00 | $404,000.00 |
| Receivables | – | – | – | $88,000.00 | $88,000.00 |
| -Accounts Receivable | – | – | – | $88,000.00 | $88,000.00 |
| -Accumulated Depreciation | – | – | – | -$1.55M | -$1.55M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$33.67M | -$31.42M | -$36.88M | -$123.34M | -$27.90M |
| Net cash flow from continuing operations | -$33.67M | -$31.42M | -$36.88M | -$123.34M | -$27.90M |
| Net Income from Continuing Operations | -$45.49M | -$43.42M | -$41.28M | -$144.74M | -$33.00M |
| Depreciation & Depletion & Amortization | $33,000.00 | $43,000.00 | $98,000.00 | $525,000.00 | $108,000.00 |
| Other Non-Cash Items | -$9,000.00 | $31,000.00 | $4.05M | -$169,000.00 | -$433,000.00 |
| Change in Working Capital | $2.53M | $4.82M | -$5.26M | -$1.08M | $92,000.00 |
| -Change in Prepaid Assets | -$5.15M | -$325,000.00 | $1.43M | $3.98M | $325,000.00 |
| -Change in Payables and Accrued Expense | $7.70M | $5.18M | -$6.66M | -$6.02M | -$934,000.00 |
| -Change in Other Current Assets | $294,000.00 | $340,000.00 | $298,000.00 | $1.73M | $295,000.00 |
| -Change in Other Current Liabilities | -$312,000.00 | -$375,000.00 | -$327,000.00 | -$1.16M | $23,000.00 |
| Net cash flow from investing | -$325.67M | -$149.80M | $36.26M | $14.04M | $29.47M |
| Net Cash Flow from Continuing Investing Activities | -$325.67M | -$149.80M | $36.26M | $14.04M | $29.47M |
| Net PPE Purchase and Sale | -$25,000.00 | -$30,000.00 | $0.00 | -$138,000.00 | -$86,000.00 |
| Net Investment Purchase and Sale | -$325.64M | -$149.77M | $40.26M | $14.18M | $29.55M |
| Net Other Investing Changes | $0.00 | $0.00 | -$4.00M | – | – |
| Financing Cash Flow | $550.16M | $1.48M | $3.22M | $257.03M | -$208,000.00 |
| Net Cash Flow from Continuing Financing Activities | $550.16M | $1.48M | $3.22M | $257.03M | -$208,000.00 |
| Proceeds from Stock Option Exercised | $11.71M | $1.97M | $7.16M | $4.08M | $376,000.00 |
| Net Other Financing Charges | $538.45M | -$494,000.00 | -$3.94M | $252.95M | -$584,000.00 |
| Ending Cash Balance | $241.09M | $50.31M | $230.12M | $227.64M | $227.64M |
| Net Change in Cash | $190.82M | -$179.74M | $2.60M | $147.73M | $1.36M |
| Beginning Cash Balance | $50.31M | $230.12M | $227.64M | $78.84M | $226.16M |
| Effect of Exchange Rate Changes | -$39,000.00 | -$68,000.00 | -$111,000.00 | $1.07M | $118,000.00 |
| Free Cash Flow | -$33.70M | -$31.45M | -$36.88M | -$123.48M | -$27.99M |
| -Change in Receivables | – | – | – | $383,000.00 | $50,000.00 |
| -Change in Inventory | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on AMLX.
Sign in to join the discussion.